We previously reported that variants in IL6, dbSNP ID rs1800795 and rs1800796, were associated with reduced risk of colon cancer among recent aspirin/nonsteroidal anti-inflammatory drug (NSAID) users [3]; the rs1800795 promoter SNP, which is in linkage disequilibrium (LD) with rs1800797 (r2 = 0.92), appeared to be greatest for TP53 mutations while rs1800796 appeared to influence all tumor types among NSAID users. This evidence concerns the gene IL6 and colonic neoplasm.